Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.64 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
| ▸ | GCLC | P48506 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057870 | 0.84 | FOLH1 (0.64) | FOLH1NAALAD2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14927203 | 0.81 | GCLC (0.59) | FOLH1NAALAD2GCLCCA2MAPK1 | |
| SCHEMBL5053176 | 0.81 | FOLH1 (0.67) | FOLH1NAALAD2CA2MAPK1SLC1A3 | |
| SCHEMBL2976105 | 0.80 | GCLC (0.48) | FOLH1NAALAD2GCLCCA2MAPK1 | |
| SCHEMBL27431060 | 0.79 | LAP3 (0.65) | FOLH1NAALAD2SLC1A3SLC1A2 | |
| SCHEMBL20610006 | 0.79 | SLC1A3 (0.52) | FOLH1NAALAD2GCLCCA2MAPK1 | |
| SCHEMBL2982756 | 0.78 | GCLC (0.47) | FOLH1NAALAD2GCLCCA2MAPK1 | |
| SCHEMBL1292849 | 0.78 | FOLH1 (1.00) | FOLH1NAALAD2 | |
| SCHEMBL6114 | 0.78 | — | — | |
| SCHEMBL7716769 | 0.78 | CYP2D6 (0.42) | FOLH1NAALAD2GCLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-6054444-A | INHIBIT N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-25 | — | — | US | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-8053059-B2 | Substrate for patterning and method for forming a pattern of nanocrystals using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-11-08 | — | — | US | disclosed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-20080182072-A1 | SUBSTRATE FOR PATTERNING AND METHOD FOR FORMING A PATTERN OF NANOCRYSTALS USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-07-31 | — | — | US | disclosed |
| US-7335410-B2 | Molding materials using metallic catalyst on phosphonic acid support | ZIMMER AG (DE) | 2008-02-26 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-04-03 | — | — | US | disclosed |
| US-6288046-B1 | ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE/N-/ INHIBITORS; CARBOXYALKYLPHOSPHATES; PROSTATE DISORDERS; GLUTAMATE ABNORMALITIES; NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-09-11 | — | — | US | disclosed |
| US-6054444-A | INHIBIT N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-25 | — | — | US | disclosed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998047906-A1 | PHOSPHONIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| US-4608207-A | Dialkyl 2-alkylcarbonatoethanephosphonates | BAYER AKTIENGESELLSCHAFT (DE) | 1986-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064912-A1 | Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors | NAALAD2, DNPEP, DPP9 | FOLH1 56/4885NAALAD2 1/4885GCLC 722/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | FOLH1 1/4885NAALAD2 208/4885GCLC 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.